3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
21
Phase 1
20
Phase 2
15
Phase 1/2
4
Phase 3
3
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
10
Thoracic
2
Gastrointestinal
2
Breast
2
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Dermatologic
1
CNS
1
Conditions
Leukemia, Myeloid, Acute
59
Precursor Cell Lymphoblastic Leukemia-Lymphoma
44
Leukemia
29
Hematologic Neoplasms
23
Myelodysplastic Syndromes
18
Lymphoma
16
Neoplasms
15
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
12
Lymphoma, Non-Hodgkin
9
Leukemia, Lymphocytic, Chronic, B-Cell
7
Graft vs Host Disease
7
Neoplasms by Site
6
Neoplasms by Histologic Type
6
Multiple Myeloma
6
Anemia, Refractory, with Excess of Blasts
6
Recurrence
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Neoplasms, Plasma Cell
5
Neoplasm, Residual
5
Leukemia, Biphenotypic, Acute
5
Infections
5
Primary Myelofibrosis
4
Lymphoproliferative Disorders
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large B-Cell, Diffuse
4
Leukemia, Myelomonocytic, Chronic
4
Leukemia, Myeloid, Chronic-Phase
4
Leukemia, Myeloid, Accelerated Phase
4
Glioma
4
Congenital Abnormalities
4
Interventions
capmatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Sarcoma
×
Other hematologic neoplasm
×
Clear all
NCT06988475
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled